Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of [18F]MK-0947 PET Imaging in Parkinson's Disease
NCT07348250Phase 1Terminated
- Sponsor
- Invicro
- Start
- Dec 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [18F]MK-0947 in Parkinson's disease (PD) (2 arms), sponsored by Invicro. Primary endpoints: Incidence of Adverse Events up to 4 months and Radiation absorbed dose estimates at 4 months. Started Dec 2025; status: terminated.
02
Drugs
[18F]MK-0947
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07348250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07348250.